000285591 001__ 285591
000285591 005__ 20240229155114.0
000285591 0247_ $$2doi$$a10.1080/23744235.2023.2277390
000285591 0247_ $$2pmid$$apmid:37994805
000285591 0247_ $$2ISSN$$a2374-4235
000285591 0247_ $$2ISSN$$a0036-5548
000285591 0247_ $$2ISSN$$a1651-1980
000285591 0247_ $$2ISSN$$a2374-4243
000285591 0247_ $$2altmetric$$aaltmetric:156754624
000285591 037__ $$aDKFZ-2023-02453
000285591 041__ $$aEnglish
000285591 082__ $$a610
000285591 1001_ $$aMorais, Samantha$$b0
000285591 245__ $$aSerologic response to human papillomavirus genotypes following vaccination: findings from the HITCH cohort study.
000285591 260__ $$aAbingdon$$bTaylor & Francis Group$$c2024
000285591 3367_ $$2DRIVER$$aarticle
000285591 3367_ $$2DataCite$$aOutput Types/Journal article
000285591 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1705658701_22126
000285591 3367_ $$2BibTeX$$aARTICLE
000285591 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285591 3367_ $$00$$2EndNote$$aJournal Article
000285591 500__ $$a2024 Jan;56(1):66-72
000285591 520__ $$aHuman papillomavirus (HPV) infection contributes to approximately 5% of the worldwide cancer burden. The three-dose HPV vaccine has demonstrated immunogenicity and efficacy. Humoral responses may be critical for preventing, controlling, and/or eliminating HPV infection. Using data from the HITCH cohort, we analysed humoral immune response to HPV vaccination among women in relation to the phylogenetic relatedness of HPV genotypes.We included 96 women aged 18-24 years attending college or university in Montreal, Canada. Participants provided blood samples at enrolment and five follow-up visits. Antibody response to bacterially expressed L1 and E6 glutathione S-transferase fusion proteins of multiple Alphapapillomavirus types, and to virus-like particles (VLP-L1) of HPV16 and HPV18 were measured using multiplex serology. We assessed correlations between antibody seroreactivities using Pearson correlations (r).At enrolment, 87.7% of participants were unvaccinated, 2.4% had received one, 3.2% two, and 6.7% three doses of HPV vaccine. The corresponding L1 seropositivity to any HPV was 41.2%, 83.3%, 100%, and 97.0%. Between-type correlations for L1 seroreactivities increased with the number of vaccine doses, from one to three. Among the latter, the strongest correlations were observed for HPV58-HPV33 (Pearson correlation [r] = 0.96; α9-species); HPV11-HPV6 (r = 0.96; α10-species); HPV45-HPV18 (r = 0.95; α7-species), and HPV68-HPV59 (r = 0.95; α7-species).Correlations between HPV-specific antibody seroreactivities are affected by phylogenetic relatedness, with anti-L1 correlations becoming stronger with the number of vaccine doses received.
000285591 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000285591 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000285591 650_7 $$2Other$$aAntibodies
000285591 650_7 $$2Other$$ahuman papillomavirus
000285591 650_7 $$2Other$$aimmunogenicity
000285591 650_7 $$2Other$$apapillomavirus vaccines
000285591 650_7 $$2Other$$aserology
000285591 7001_ $$aWissing, Michel D$$b1
000285591 7001_ $$aKhosrow-Khavar, Farzin$$b2
000285591 7001_ $$aBurchell, Ann N$$b3
000285591 7001_ $$aTellier, Pierre-Paul$$b4
000285591 7001_ $$aCoutlée, François$$b5
000285591 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b6$$udkfz
000285591 7001_ $$aEl-Zein, Mariam$$b7
000285591 7001_ $$aFranco, Eduardo L$$b8
000285591 773__ $$0PERI:(DE-600)2805836-7$$a10.1080/23744235.2023.2277390$$gp. 1 - 7$$n1$$p66-72$$tInfectious diseases$$v56$$x2374-4235$$y2024
000285591 909CO $$ooai:inrepo02.dkfz.de:285591$$pVDB
000285591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000285591 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000285591 9141_ $$y2023
000285591 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINFECT DIS-NOR : 2022$$d2023-10-26
000285591 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000285591 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000285591 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000285591 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000285591 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000285591 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000285591 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000285591 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000285591 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-26
000285591 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000285591 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000285591 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-26
000285591 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINFECT DIS-NOR : 2022$$d2023-10-26
000285591 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x0
000285591 980__ $$ajournal
000285591 980__ $$aVDB
000285591 980__ $$aI:(DE-He78)F020-20160331
000285591 980__ $$aUNRESTRICTED